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 Cancer immunotherapy works by taking a patient’s existing immune system and priming 
it to recognize cancer cells in order for immune cells to mount an effective response to the 
disease.  This is a less invasive means of treating cancer for the patient. However current 
immunotherapy does come with its own unique side effects such as auto immune disorders that 
manifest in the patients’ treatment due to the blocking of essential immune regulatory 
checkpoints. In this study, patients are treated with drugs nivolumab and pembrolizumab, both of 
which are PD-1 (Programmed Death Receptor 1) monoclonal antibodies. These antibodies bind 
to PD-1 and prevent ligand interaction with PD-L1. PD-1 is a receptor expressed on the surface 
of activated B-cells, macrophages and T-cells. When PD-1 is activated by PD-L1 a signal 
propagates from the receptor to inside the cell that results in the apoptosis of the cell that 
expresses PD-1. The activation of PD-1 on activated T-cells ultimately results in a reduction of 
T-cell proliferation and IFN-γ secretion. An apoptotic signal occurs through the inhibition of the 
cell survival signal that is propagated through the PI3K pathway. While there is knowledge on 
how the expression and activation of PD-1 on immune cells regulates the progression of cancer, 
there is a lack of evidence to suggest biomarkers in non-small cell lung cancer patients for 
optimizing immunotherapy. This study serves to identify biomarkers in non-small cell lung 
cancer patients undergoing PD-1 monoclonal antibody immunotherapy. To accomplish this, 
blood samples were collected from non-small cell lung cancer patients undergoing the 
immunotherapy treatment and the cell counts were taken. Cell types of interest include cytotoxic 
T-cells, helper T-cells, B-cells, and granulocytes. Cytotoxic T-cells were identified by CD8 
expression, a known marker of cytotoxic T-cells. Helper T-cells were identified by CD4 
expression and B-cells were identified by CD19 expression, both of which are known markers of 
helper T-cells and B-cells, respectively. Secondly, this study investigated the expression levels of 
known immune regulatory genes and how these changed over the course of the immunotherapy 
treatment. Known immune regulatory genes included PD-L1, PD-1, CTLA4, CD28, A2A, CD80 
and CD86. The expression levels of the proton sensing family of G-protein coupled receptors 
(G2A, GPR4, OGR1 and TDAG8) were also investigated. Thirdly, we investigated how tumor 
cell expression of PD-1 and PD-L1 was altered when introduced into an acidic environment. Due 
to the tumor microenvironment being characteristically acidic this would provide insight on how 
anti PD-1 and anti PD-L1 immunotherapies could potentially be used in various cancers and may 
also lead to the development of potential future combination therapies. Our study shows that 
approximately 90% of patients exhibited an increase in cytotoxic T-cell counts with 50% of 
patients achieving healthy donor cytotoxic T-cell counts after receiving immunotherapy. 
Additionally 2 patients out of the total 16 patients achieved and sustained cytotoxic T-cell counts 
above that of healthy donors. There was an observable trend that indicated a possible correlation 
that PD-1 levels at baseline could predict patient response to the PD-1 monoclonal antibody 
immunotherapy. In addition to our research into the clinical aspects of PD-1 monoclonal 
antibody immunotherapy, we also investigated the change in expression of PD-1 and PD-L1 
mRNA in several cancer cell lines. We observed that there was a variation in how cancer cells 
responded to acidosis. PD-1 and PD-L1 mRNA expression was shown to be regulated through 
several variables such as the acidity of the media, duration of exposure to acidic conditions and 
cancer cell type. It was also observed that there was PD-1 and PD-L1 expression in these cancer 
cell lines, at 5 hour and 24 hour treatment times, with a prominent level of PD-L1 mRNA 
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Chapter 1: Introduction 
 The Tumor Microenvironment 
 Cancer is a disease that develops when healthy cells become malignant and continuously 
divide and spread. This causes dysfunction in the tissue that cancer presents itself in. To 
understand the Tumor Microenvironment (TME) it is crucial to first recognize that cancer cells 
are cells that do not follow normal cell protocol which dictates what conditions a cell can divide 
and the number of times a cell can divide. Instead, cancer cells operate in a nearly autonomous 
manner. There are many forms of cancers and each one is unique to the organ in which it 
metastasizes in based off of the proteins that these cancer cells display and the pathways they 
elicit to survive and proliferate. However, though there are differences amongst various cancer 
types there are 6 characteristics displayed in all cancers. These characteristics have come to be 
referred to as the “Hallmarks of Cancer” and include the following: the ability to sustain 
proliferative signaling, evasion of growth suppressors, the ability to invade other tissues and 
metastasize, and displaying replicative immortality, induction of angiogenesis and resistance of 
cell death45. Proliferation is a closely regulated trait in all cell types as it requires the 
consumption of resources to achieve this division of cells. Cell growth is maintained through the 
cell cycle which requires key proteins to initiate and sustain cell survival signals in order to 
achieve cell homeostasis45. Cancer cells have evolved in a fashion so that they can bypass key 
regulators in these proliferative growth steps that then allow the cancer cells to function in an 
independent manner. By hijacking these signals that control the cell cycle, cancer cells are able 
to dictate when to divide despite whether or not there are adequate enough resources to do so. 
Cancer cells possess the capacity to continuously replicate in an exponential manner, allowing 




increased proliferation, cancer cells are also able to resist cell death through the inhibition of 
apoptotic signals and appear to be immortal as they divide indefinitely where normal cells can 
pass through a limited number of successive cell growth-and-division cycles45. A cancer cell is a 
cell that is able to bypass any inhibitory checkpoints on cell growth and can then divide 
continuously until the needs of the cancer cells impede physiological conditions within the body 
and result in organ failure in the tissue that they have metastasized to1-3,24. It is believed that this 
ability for cancer cells to divide indefinitely in an immortal fashion is due to a lack of telomere 
shortening as ~90% of immortalized cells express telomerase, the enzyme that prevents 
telomerase shortening, at significantly high levels 27. Cancer cells have also displayed the ability 
to induce the formation of blood vessels, thus initially increasing blood perfusion to the tumor 
although this increased perfusion is not sustained in the tumor. Tumor induced angiogenesis is 
not as efficient as physiological angiogenesis. Tumor associated endothelial cells (TEC) often do 
not adhere as well to each other as normal endothelial cells of a blood vessel do and therefore 
result in blood vessels that are characterized as unstable or leaky5. 
 Previously it has been observed that when producing the cellular energy source adenosine 
triphosphate (ATP), cancer cells will avoid oxidative phosphorylation and instead enter into 
glycolysis5. By shifting into glycolysis as opposed to the higher energy yielding oxidative 
phosphorylation, the tumor produces energy at a lower rate and produces byproducts such as 
lactic acid. An abundance of lactic acid will then result in a decrease in the pH of the tumor 
microenvironment. Decreases in pH in the tumor microenvironment have been attributed to 
features of cancer progression such as local tumor invasion and distant metastatic spread45. 
Additionally, an increase in the transcription of vascular endothelial growth factor (VEGF) was 




attributed to increased hypoxic conditions in the TME which resulted in increased production of 
Hypoxia Inducible Factor 1-α (HIF1-α) which is responsible for the upregulation of VEGF. 
Increased VEGF then resulted in the formation of the blood vessels to supply cancer cells with 
nutrients for glycolysis, producing lactic acid and yielding the characteristically low pH of the 
TME5. 
The Warburg Effect 
 It is a common fact of biology that a normal cell’s means of energy production is through 
oxidative phosphorylation that occurs in the mitochondria of cells with the exception of more 
rapidly proliferative cells such as endothelial cells and lymphocytes29. Due to their high rate of 
proliferation, rapidly proliferative cells utilize anaerobic glycolysis to serve as their main energy 
source due to its faster, though inefficient, rate of energy production and the generation of 
metabolic intermediates for biosynthesis. The Warburg effect is a phenomenon observed in most 
cancer cells where these cancer cells utilize glycolysis to produce the mass of their energy 
despite a possible adequate oxygen supply. This pathway is less efficient than the citric acid 
cycle and also bypasses the cell’s mitochondria which led to Warburg’s original hypothesis that 
there was dysfunction associated with the energy producing processes of the mitochondria in 
these cancer cells and suggested that these malignant cells may depend on glycolysis for their 
ATP production rather than the more efficient citric acid cycle that occurs in mitochondria 25. 
However, several studies have shown that most cancers have functional mitochondria but are 
being bypassed during energy production in these cancer cells29. Several oncogenes such as p53, 
were originally thought to only mitigate aspects of the cell cycle but have now been attributed to 
maintaining homeostasis of cell metabolism as well5.  By not going through oxidative 




as much less ATP is produced per glucose molecule and lactic acid is produced. Normal cells 
will take pyruvate, the byproduct of glycolysis, and process this through the citric acid cycle 
producing the energetic compound NADH which donates protons to be shuttled through the 
electron transport chain to yield higher amounts of ATP. Malignant cells that have a higher rate 
of glycolysis than normal cells, do not process glucose in the same metabolic manner as normal 
cells. Once malignant cells convert glucose to pyruvate it is then converted to lactic acid28. This 
lactic acid builds up in the tumor and aids in the acidic nature of the Tumor Microenvironment. 
 It was originally postulated by Otto Warburg that this change in metabolism was thought 
to contribute to malignancies in normal cells which came to later be referred to as the “Warburg 
Hypothesis.” Today, mutations in genes that are responsible for maintaining normal cell 
homeostasis (otherwise referred to as oncogenes) are thought to be the cause of malignant 
formations and the observed metabolic changes are assumed to be a product of this and not a 
cause, as was originally believed 26,27. 
Acidosis in Cancer 
 Due to Otto Warburg’s original observations in 1924, it is now well known in the field of 
cancer that most cancer cells have altered metabolisms when compared to normal cells25-27. And 
it is also well known that a byproduct of this altered metabolism is lactic acid28. However, it is 
still debated whether or not the lactic acid produced by cancer cells is simply a byproduct of their 
energy production or if the lactic acid serves a specific role in cancer progression and metastasis. 
Some reports indicate that this increase in lactic acid serves to aid tumor cell growth as the 
increased lactic acid helps regulate cell growth pathways in a manner that favor cancer cell 
growth. Lactic acid has also been shown to decrease penetration of dendritic cells into tumor cell 




Additionally, lactic acid has been observed to increase tumor cell motility and thus increase the 
rate of metastasis33. Prior to this observation that lactic acid was directly responsible for this 
increased metastasis, scientists had observed a high rate of glycolysis in cancer cells which was 
assumed to be solely for energy production33. It was later observed that this increased glycolysis 
was a means of achieving acidic conditions in the TME through the production of carbonic acid 
in addition to lactic acid. One of the means in which acidosis increases tumor growth is through 
the regulation of the Vascular Endothelial Growth Factor (VEGF) protein. By decreasing the pH 
in the tumor microenvironment, the production of VEGF is increased by HIF1-α which is 
upregulated in hypoxic conditions. This increase in VEGF allows for increased vascularization in 
the tumor which allows for a greater supply of nutrients throughout the tumor, allowing for 
greater tumor cell proliferation30. Furthermore, increases in the vascularization of the tumor 
increases tumor proliferation by increasing the abundance of glucose to the tumor, resulting in 
further acidification of the TME, thus creating a positive feedback loop30. It is possible that 
acidosis in the TME could have other effects on tumor growth through regulation of proteins 
involved in the regulation of cell division, metabolism, apoptosis and vascularization.  
The Immune System and Cancer 
 The immune system is the body’s defense against bacteria, viruses and various agents of 
disease. It can be divided into two categories, the innate and the adaptive immune systems. The 
innate immune system is the first responder to infection and is comprised of granulocytes, 
natural killer cells, mast cells, macrophages and dendritic cells. The adaptive immune system 
differs from the innate immune system in that the adaptive immune system, unlike the innate, 
can alter its immune profile so that it can detect pathogens that the adaptive immune cells have 




each pathogen that it encounters by learning to distinguish proteins that are readily expressed on 
each unique pathogen. The innate immune system is a first response defense that is less 
specialized at detecting and combating pathogens than the adaptive immune system.  While the 
adaptive immune system is more critical on what is allowed to survive within the host through 
the recognition of proteins that distinguish healthy cells from pathogens or diseased cells the 
innate immune system does not have as thorough of a screening process and will instead attempt 
to attack and eliminate most foreign bodies it encounters. The cells of the adaptive immune 
system include cytotoxic T-cells, helper T-cells and B-cells. These three lymphocytes of the 
adaptive immune system work together to activate and prime effector cells to recognize and 
terminate any foreign body encountered. Each cell of the immune system serves its own specific 
role in detecting and combating diseases. Antigen presenting cells (APC) such as dendritic cells, 
B-lymphocytes and macrophages serve to aid in the priming of effector cells for attack against 
specific antigens of diseased cells. Cytotoxic T-cells and Natural Killer cells are responsible for 
directly combating these diseased cells. B-lymphocytes and other antigen presenting cells serve 
to internalize any pathogen that is encountered and bind identifiable proteins to a major 
histocompatibility complex (MHC) within the B-cell. However, B-cells are not the only cells 
responsible for antigen presentation and effector cell activation. Dendritic cells also serve the 
purpose of effector cell activation through antigen presentation, but do not belong to the adaptive 
immune system as dendritic cells are seen as members of the innate immune system. Both B-
cells and dendritic cells take pathogenic proteins or antigens that they internalize from the 
external environment and complex the antigen to MHC molecules for antigen presentation.  This 
MHC-protein complex is then localized to the surface of antigen presenting cells where it can 




to each T-cell type while the T-cell Receptor (TCR) recognizes the antigen that is bound to the 
MHC complex. Upon presentation of the MHC-protein complex, T-cells will then receive 
costimulatory signals to prime and activate them to effector T-cell status. Different T-cells 
require different stimulatory signals. T-Helper cells receive stimulatory signals from the binding 
of CD4 to the MHC Complex as well as from CD28 and CD40 binding to their ligands expressed 
on the APC. Cytotoxic T-cells receive their costimulatory signal from CD8 binding to the MHC 
complex and through CD28 binding to its ligands CD80/ CD86 on the APC. Cytotoxic T-cells 
recognize MHCI complexes while T-Helper cells recognize MHCII complexes. Upon 
presentation of the MHC complexed with an antigen, the T-cells differentiate into T-helper cells, 
memory T-cells, regulatory T-cells and effector T-cells.   
Effector T-cell Activation and Priming 
 As previously mentioned, the immune system can be broadly divided into two categories; 
the adaptive immune system and innate immune system. Most current immune therapies focus 
on the cells of the adaptive immune system and how best they can be utilized to diminish the 
metastasis of cancer and for this reason, the focus of this section will be directed towards the 
adaptive immune system and the roles that the various adaptive immune cells play in immune 
response. The following paragraphs serve to discuss the activation of the lymphocytes of the 
adaptive immune system as well as how these cells are primed to recognize and attack cancer 
cells and other pathogens. 
 The adaptive immune system is comprised of a variety of cells. These cells include: 
Cytotoxic T-cells, T-helper cells, B-cells and debatably dendritic cells and natural killer T-
cells37. Dendritic cells are antigen presenting cells that serve to bridge the innate and adaptive 




innate immune system and complexing these pathogenic antigens to MHC molecules37, 39. These 
MHC antigen complexes are then presented to T-cells to prime the T-cells to recognize and 
attack cells expressing this displayed antigen. Natural killer cells are effector cells of the innate 
immune system that work in a similar manner as effector T-cells but are not dependent on 
antigen presentation to elicit an effector cell response to a stressed cell and typically function 
without the need for antigen recognition38. Recently it has been shown that natural killer cells do 
respond more efficiently to secondary infections due to a small capacity to recognize antigens 
that natural killer cells had previously encountered on diseased cells, thus displaying 
immunological memory within natural killer cells40. Natural killer cells are differentiated from 
lymphoid progenitor cells that are responsible for producing B-lymphocytes and T-lymphocytes 
of the adaptive immune system39. It is through the adaptive immune system that vertebrates are 
able to recognize and build a defense to pathogens through the use of immunological memory. 
Immunological memory is the capacity of immune cells to catalog information within their cells 
in the form of antibodies37. These antibodies are specific for antigens that were previously 
encountered by cells of the innate and adaptive immune systems. These antibodies are released 
when a previously encountered pathogenic antigen is recognized. The released antibodies then 
bring about the activation of effector T-cells to rid the body of the present pathogen37,39,41. There 
are two types of cells in the adaptive immune system that are responsible for managing 
immunological memory, memory T-cells and memory B-cells37. This immunological memory 
then prevents these pathogens from afflicting the host’s body so poorly in the future. However, 
this recognition and combating of disease is made possible through cells of the adaptive immune 
system being able to recognize pathogen associated molecular patterns (PAMPs) expressed on 




 For the adaptive immune system to build a response to a certain pathogen, it must first 
encounter the pathogen and process it so that it can be recognized in the future and then be 
disposed of by effector T-cells. To achieve this goal, a pathogen must first encounter an antigen 
presenting cells37. Antigen presenting cells are cells that are responsible for internalizing proteins 
expressed on pathogens and pairing them with a Major Histocompatibility (MHC) complex. This 
MHC complex is a protein that is recognized by certain effector cell types and aids in the 
priming of these effector cells so the cells can then recognize pathogens that express the protein 
that is bound to the presented MHC complex. In the adaptive immune system dendritic cells, 
macrophages, and B-Lymphocytes fill the role of antigen presenting cells and interact with naïve 
CD4+ T-cells and naïve CD8+ T-cells, activating the T-cells, causing them to differentiate37. 
CD4 is a molecular marker expressed on helper T-cells. CD8+ is a protein marker expressed 
exclusively on cytotoxic T-cells. Naïve CD4+ T-cells can further differentiate into the sub 
categories: T-memory cells, regulatory T-cells and T-helper cells upon activation by B-cells. T-
memory cells serve to retain the PAMP from the initial pathogen for future encounters. 
Depending on the type of T-memory cell there can be two possible responses to secondary 
infection. If the T-memory cell is CCR7 deficient it is referred to as an effector memory cell and 
will display a pro-inflammatory phenotype and secrete cytokines IFN-γ, IL-5 and IL-441. These 
effector memory T-cells will migrate to inflamed tissue where the cells then assume an effector 
cell phenotype. If the T-memory cell does have CCR7 receptors than it does not display a pro-
inflammatory phenotype but activates dendritic cells instead41. Regulatory T-cells negatively 
regulate cytotoxic T-cells in order to keep cytotoxic T-cell counts from growing excessive and 
prevent an auto immune response. T-helper cells aid the adaptive immune system by helping to 




which has shown to aid in the maturation of naïve CD8+ T-cells to active effector T-cells41,42. 
When a naïve CD8+ T-cell encounters an antigen presenting cell with an antigen paired to its 
MHC complex it is activated in a similar fashion as the naïve CD4+ T-cells. These activated 
naïve CD8+ T-cells then differentiate into effector cytotoxic T-cells, responsible for directly 
attacking stressed cells or agents of disease, and memory CD8+ T-cells, which circulate 
throughout the lymphatic system indefinitely to retain this antigen specific response. 
 For the process of T-cell activation to take place and the subsequent differentiation into 
T-helper cells and Cytotoxic T-cells, a series of activating signals must first be received. Once an 
antigen presenting cell has internalized an identifying protein of a pathogen it then pairs antigen 
to the MHC complex. This antigen-MHC complex is then localized to the surface of the APC 
which in the adaptive immune system is represented by B-cells. These B-cells then pair with T-
cells to prime and activate them. Antigens presented by B-cells are recognized by T-cell 
receptors that are expressed on the membranes of T-cells while the MHC complex is recognized 
and held in place by the proteins CD4 and CD8 which are expressed on T-helper cells and 
Cytotoxic T-cells, respectively37-39. CD4 recognizes MHCII and CD8 recognizes MHCI. In 
addition to the activation signals received through TCR binding there are costimulatory signals 
occurring during this activation process. In both CD4+ and CD8+ T-cells the protein CD28, a 
costimulatory protein, is expressed. This CD28 protein binds to CD80-CD86 complex (B7) 
expressed on the APC. This CD28/ B7 binding then results in the propagation of a costimulatory 
signal in the T-cell, aiding in its activation. In addition to CD28 T-helper cells have another 
costimulatory protein known as CD40. When CD40 binds to its ligand CD40L that is expressed 





 Effector T-cells, much like tumor cells, utilize aerobic glycolysis as a means of producing 
energy. It has been observed that this transition of glucose to lactate in the presence of oxygen to 
produce energy is essential for effector T-cell activation35. The current theory is that this use of 
aerobic glycolysis to produce energy rather than the utilization of the much more economical 
oxidative phosphorylation is due to the high proliferation rate of T-cells that is necessary for 
these cells to be able to mount attacks against diseased cells such as cancer cells. The byproducts 
of the aerobic glycolysis are then shuttled out of the activated effector T-cells through 
monocarboxylate transporters (MCT) with the most frequently used lactate transporter being 
MCT-1, which functions in a gradient dependent manner35. This shuttling of lactate from the T-
cell then allows for the lactate molecule to be converted back into pyruvate and then back into 
glucose at the cost of 6 ATP, thus completing the Cori Cycle. Because tumor cells also utilize 
aerobic glycolysis as a means of energy production to fuel their rapidly proliferating nature, they 
too produce byproducts of aerobic glycolysis such as lactate. This then results in an acidic Tumor 
Microenvironment (TME) as is characterized by the Warburg Effect. This increase of lactic acid 
in the TME results in the blocking of the gradient dependent lactate shuttle MCT-1 that is 
expressed on the effector T-cells. This inability to rid the T-cell of the produced lactate results in 
the cell being unable to perform necessary tasks by having reduced IL-2, IFN-γ, perforin and 











Role of Monoclonal Antibodies (mAbs) in Cancer Therapies 
Antibodies are proteins that are mainly excreted by a subset of cells of the immune 
system known as plasma cells, a specialized B-lymphocyte. Antibodies can be soluble and thus 
circulate freely through the blood/ lymphatic system unbound to cells where they can directly 
bind antigens and inhibit disease progression through activation of the bound protein37,39. 
Antibodies can also be bound to cells and aid in immune cell response. These antibodies are 
responsible for the recognition of antigens as well as the presentation of these antigens to 
effector cells that are then primed for attack against cells that express these antigens. The epitope 
is a region on antigens that is recognized by antibodies via a region of their anatomy known as 
the paratope. This paratope is contained within the variable region of the Fab within the 
antibody. A collection of antibodies that can recognize multiple epitopes are referred to as 
polyclonal antibodies while a collection of antibodies that can only recognize one epitope due to 
there being only one type of paratope present are referred to as monoclonal antibodies. 
Additionally, monoclonal antibodies are derived from a single lineage of cells while polyclonal 
antibodies are produced and secreted by different B-lymphocyte lineages within the immune 
system. 
 Today the administration of antigen specific monoclonal antibodies (mAbs) to cancer 
patients has become a very common practice as can be seen in lymphoma and leukemia patients 
that are treated with the CD20 (a B-Lymphocyte antigen) antibody Rituximab36. Through the 
implementation of mAbs to fight cancer, immunotherapy has become a much more common 
practice for the treatment of cancer. Unlike chemotherapy that targets DNA replication and thus 
targets any dividing cell, mAbs work by specifically targeting the cells of the immune system 




the recognition of certain lineage specific antigens (LSA) which are antigens whose expression is 
largely limited to a certain subset of leukocyte or tissue34. These mAbs bind to antigens and 
prevent interaction with other proteins expressed on cancer cells, thus preventing cancer cells 
from interacting with these immune cells in a negative fashion. However, there are also non-
lineage specific antigens (NLSA) which are antigens that are not limited to only being expressed 
on a certain subset of cells34. These NLSA have shown to play various roles in the regulation of 
key cells that are involved in slowing cancer progression. It is for this reason that a large variety 
of mAbs have been designed to target each of these unique antigens. These NSLA mAbs serve to 
block several tumor promoting pathways and some have been designed to even deliver cytotoxic 
drugs by engineering these antibodies to attach to the drugs and then releasing the drug in the 
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Role of PD-1/ PD-L1 in the Immune System Regulation of Cancer 
 As previously stated, one of the hallmarks of cancer is the ability to evade inhibitory 
growth signals. When inhibitory growth signals are not established in cancer cells, cells grow 
and proliferate in number in an exponential manner. One of the means that cancer cells avoid 
these inhibitory signals is by evasion and manipulation of cells of the immune system that are 
responsible for detecting cancer cells and ridding the body of them45. There are various 
mechanisms that cancer cells implement to avoid detection by the immune system. Within the 
last few years one of these immune regulators to as PD-1/ PD-L1 has gained a lot of recognition 
as an effective target for cancer treatment. The protein PD-1 (programed cell death protein 1) is 
referred to as an immune checkpoint receptor due to its ability to regulate the counts of any cells 
that it is expressed on through the induction of apoptosis within these PD-1 expressing cells1-3, 24. 
It has been shown that PD-1 has a high level of expression on cytotoxic T-cells which are the 
cells of the adaptive immune system that are responsible for the recognition and destruction of 
cancer cells. When PD-1 is activated by its ligand (PD-L1) an inhibitory signal is passed on 
through the cells possessing the activated PD-1. This inhibitory signal then suppresses the PI3K 
pathways which is responsible for cell survival. When the PI3K pathway is inhibited, cell 
survival declines and cell count decreases. In the case of cytotoxic T-cells this means that there 
are less effector T-cells to slow the metastasis of cancer and infections as the T-cells expression 






G-Protein Coupled Receptors (GPCRs) 
 Cells utilize a variety of methods for communication with the surrounding environment. 
G-protein coupled receptors (GPCRs) are one of the means utilized by cells to communicate with 
and respond to the external environment. A GPCR is a protein that when activated results in the 
propagation of a signal to its coupled G-protein, resulting in the activation of the G-protein. G-
proteins are hetero trimeric proteins whose activation depends on the presence or absence of 
GTP/ GDP. G-proteins are comprised of alpha, beta and gamma subunits. It is now known that 
both the alpha and beta-gamma subunits can transduce signals when activated by a receptor that 
they are coupled to4-6. When GTP is present the G-protein is referred to being in its “active” 
state. G-proteins are no longer in their active state when the GTP is converted to GDP. The 
conversion of GTP to GDP is catalyzed by the GAP (GTPase-activating proteins) which bind to 
activated G-proteins and activate GTPase activity. Conversion of a G-protein to its active state is 
achieved by the enzyme GEF (guanine nucleotide exchange factor) which exchanges a bound 
GDP for a GTP.  
 The responses that G-proteins trigger in cells depends on the type of alpha subunit that 
makes up the G-protein. There are four recognized classes of G-protein alpha subunits: Gαs, Gαi/o, 
Gαq/11, Gα12/13. The Gs alpha subunit activates the cAMP-dependent pathway. This is achieved by 
activation of adenylyl cyclase, the protein responsible for cyclic AMP (cAMP) production. This 
cAMP then activates downstream effectors, one of these downstream effectors is protein kinase 
A (PKA). PKA phosphorylates key proteins such as AKT within cells to maintain homeostatic 
conditions. AKT is a protein that is crucial to glucose metabolism within cells. PKA is 




as NF-κB and thusly correlates to PKA inducing cell dependent responses. The Gi/o alpha subunit 
is the balance to the Gs alpha subunit because while the Gαs activates cAMP production, Gαi/o 
inhibits cAMP production by inhibiting adenylyl cyclase activation. Much like activation of 
PKA via the Gαs, the Gq alpha subunit is responsible for the activation of phospholipase C (PLC) 
which has the downstream effect of activating protein kinase C (PKC). Protein Kinase C is very 
similar to Protein Kinase A from the Gαs pathway due to both proteins being able to regulate 
other proteins by modulating them when adding a phosphate group to these target proteins. 
Additionally, the Gq pathway also results in increased intracellular calcium levels due to IP3, 
which is synthesized by activated PLC cleaving PIP2 into DAG and IP3, binding to calcium 
channels of the endoplasmic reticulum (ER) and resulting in a flux of calcium ions from the ER 
to the cytosol. The Gα12/13 subunits regulate actin cytoskeletal remodeling and have been shown 
to induce migration in endothelial cells through association with tyrosine kinase receptors31,32. 
 Within the class of receptor proteins known as G-Protein Coupled Receptors (GPCRs) 
there is a subclass of GPCRs known as Class A GPCRs which account for 85 percent of GPCRs. 
Within the Class A GPCRs there are proteins that have shown an affinity to protons and have 
been rightly dubbed the proton sensing family of GPCRs. These GPCRs gain their affinity for 
protons through the ability of histidine residues on the receptors being protonated by free 
protons. This family of proton sensing GPCRs consists of the 4 GPCRs: TDAG8 (GPR65), 
OGR1(GPR68), GPR4 and G2A (GPR 132). TDAG8 (T-cell death associated gene 8) is a 
protein that was first discovered on T-cells and attributed to cell death on T-cells when it was 
activated. Since its initial discovery, TDAG8 has been observed to be expressed on other cells 
aside from just T-cells. In addition to the proton sensing GPCRs there is another GPCR that has 




a GPCR that is responsible for the recognition of adenosine. A2A is activated upon encountering 
adenosine this then results in the receptor coupling to Gs and increasing adenylate cyclase 
activity. This then results in the completion of the Gs pathway which ends with activated PKA 




Chapter 2: Materials and Methods 
 Research samples relied heavily on blood collected from non-small cell lung cancer 
patients undergoing anti PD-1 immunotherapy. Because of the use of human patients there was a 
clinical side which included administration of the drugs and the collection of the blood samples 
and there was the lab research aspect side of the data collection as well. The clinical aspect of 
this research was handled by certified health care professionals while I was responsible for the 
processing of the blood samples once they had been collected by the nurses on duty at the time. 
Additionally the cancer cell lines used: Jurkat human T-cell leukemia, PC-3 human prostate 
cancer, MCF7 human breast cancer, Caki-1 human kidney cancer, Hela human cervical cancer 
cells, NCI-H1299 human lung cancer, CRL-1596 Ramos Human B Lymphoma, CRL-1619 A375 
human melanoma, SK-OV-3 human ovarian adenocarcinoma, and U937 human monocyte were 
all originally from American Type Culture Collection (ATCC). 
Clinical Trial 
 Non-small cell lung cancer patients were recruited and scheduled to come in every 2 
weeks for a 16 week period, yielding a total of 8 visits per patient. At each patient visit the on 
hand medical staff would draw a blood sample before administration of the anti PD-1 
monoclonal antibodies. Patients were taken off the trial if the physicians in charge of that patient 
saw a decrease in the patients overall health or when the patient expired. If a patient successfully 
completed the full trial then, 8 blood samples would have been collected (averaging 1 sample per 
patient every 2 weeks) during the treatment and a final blood sample would be collected 2 weeks 
after the last dose was administered to the patient, bringing the total possible number of blood 











Isolation of Immune Cells from Blood Samples 
 Blood samples were collected by medical professionals that were present on the days that 
each patient came in for their immunotherapy treatment. Up to 10 milliliters of blood was 
collected per patient sample for the cell isolation process. Once the blood samples were obtained 
they were transported in a sterile fashion to the lab. Once in a sterile environment a measured 
volume of the patient blood was taken and mixed with an equal volume of Phosphate Buffered 
Saline (PBS) (Gibco). This mixture of blood and PBS was then gently layered over a volume of 
Ficoll-Paque PLUS (GE Healthcare) in a 50ml conical tube. The Ficoll-Paque volume was ¾ the 
volume of the combined blood and PBS mixture. After layering there was a clear Ficoll layer at 
the bottom of the tube with the blood mixture suspended above this with no mixing of the two 
layers. The conical tube containing the layered ficoll and blood was then gently placed into a 
centrifuge, taking care not to mix the two layers, and then centrifuged for 40 minutes at 400x g. 
At the end of the 40 minute centrifugation there were 5 distinct bands present in the tube 
(Diagram 3). At the top was the plasma layer, below this was the Mononuclear cell (MNC) layer, 
below this was a clear ficoll layer (largely devoid of any cells), below the ficoll layer was a thin 
granulocyte layer that was then followed by a crimson red layer at the bottom of the tube which 
was largely comprised of erythrocytes (RBC). The plasma layer was removed first while taking 
care not to remove any cells from the MNC layer. This plasma was then frozen down in vials at   
-80 oC. Any residual plasma on top of the MNC layer was removed and discarded. The MNC 
layer was then placed in a 50ml conical tube and 3 volumes of PBS were added and the total 
cells were counted at this point using a hemocytometer. The MNC were then centrifuged for 15 
minutes at 400*g and the supernatant was then removed. The pellet was again suspended with a 




counted using a hemocytometer. Then using the equation (y=x*25) with “x” being the number of 
10e7 MNC and “y” being the volume (ul) of dynabeads needed to properly isolate that many 
cells, the volume of dynabeads was calculated. The MNC were then centrifuged again for 15 
minutes at 400*g and then suspended in isolation buffer to a concentration of 10e7 cells/ml. The 
CD8+ dynabeads were washed in a 5ml test tube with 1ml of isolation buffer and then placed in 
a magnet for 1 minute at which point the supernatant was removed with the tube containing the 
washed beads still in the magnet. The dynabeads were then suspended to their original calculated 
volume using isolation buffer and the MNC were then added and left to incubate at 4oC for 20 
minutes with gentle rocking. Once incubation of CD8+ cells had concluded, the cells were 
placed in the magnet again for two minutes, following this 2 minute period, the supernatant was 
removed while the tube was still in the magnet and the supernatant was then added to CD4+ 
dynabeads that were washed during the 20 minute incubation. The CD4+ cells/ beads were then 
incubated for 20 minutes at 4°C with gentle rocking. The tube containing the CD8+ cells was 
then removed from the magnet and the bead bound cells were washed with 1ml of isolation 
buffer and placed in the magnet for 2 minutes at which point the supernatant was discarded with 
the tube still in the magnet and another 1ml of isolation buffer was added to the bead bound cells 
and placed in the magnet again for 2 minutes. Once the 2 minutes had passed, the supernatant 
was discarded and the cells were suspended in 1.5ml centrifuge tubes with 1ml of isolation 
buffer at which point they were then counted using a hemocytometer and smear slides were 
made. The cells were then placed back into the magnet for 2 minutes and the supernatant was 
discarded leaving just the bead bound cells. Once the supernatant was removed for a final time 




 Once incubation of CD4+ cells had concluded, the cells were placed in the magnet again 
for two minutes, following this 2 minute period, the supernatant was removed while the tube was 
still in the magnet and the supernatant was then added to CD19+ dynabeads that were washed 
during the 20 minute incubation. The CD19+ cells/ beads were then incubated for 20 minutes at 
4°C with gentle rocking. The tube containing the CD4+ cells was then removed from the magnet 
and the bead bound cells were washed with 1ml of isolation buffer and placed in the magnet for 
2 minutes at which point the supernatant was discarded with the tube still in the magnet and 
another 1ml of isolation buffer was added to the bead bound cells and placed in the magnet again 
for 2 minutes. Once the 2 minutes had passed, the supernatant was discarded and the cells were 
suspended in 1.5ml centrifuge tubes with 1ml of isolation buffer at which point they were then 
counted using a hemocytometer and smear slides were made. The cells were then snap frozen 
and placed on metal beads at -80°C. 
 Once incubation of CD19+ cells had concluded, the cells were placed in the magnet again 
for two minutes, following this 2 minute period, the supernatant was removed while the tube was 
still in the magnet and the supernatant (containing the other MNC population) was then added to 
a 1.5ml centrifuge tube, these cells were then counted using a hemocytometer and smear slides 
were made using the cells. The other MNC population was then centrifuged for 10 minutes at 
400*g, the supernatant was then removed and the pellet was snap frozen. The tube containing the 
CD19+ cells was then removed from the magnet and the bead bound cells were washed with 1ml 
of isolation buffer and placed in the magnet for 2 minutes at which point the supernatant was 
discarded with the tube still in the magnet and another 1ml of isolation buffer was added to the 
bead bound cells and placed in the magnet again for 2 minutes. Once the 2 minutes had passed, 




isolation buffer at which point they were then counted using a hemocytometer and smear slides 
were made. The cells were then snap frozen and placed on metal beads at -80°C. 
The remaining ficoll was discarded leaving only the granulocyte layer and the erythrocyte 
layer left in the conical tube. Red Blood Cell Lysis buffer was then added to the 50ml conical 
tube that contained the granulocytes and erythrocytes and the mixture was set to gently rock for 
15 minutes at room temperature. The granulocyte/ erythrocyte mix was then centrifuged for 15 
minutes at 400*g. After centrifugation the supernatant was aspirated, leaving behind a pellet of 
granulocytes and erythrocytes. This pellet was dissociated in another RBC Lysis and rocked for 
15 minutes at room temperature after which it was centrifuged for 15 minutes at 400*g. After 
centrifugation, the supernatant was removed and the granulocyte pellet was suspended in 40ml of 
PBS and these cells were then counted using a hemocytometer. The cells were then spun down 
for a final time for 15 minutes at 400*g and snap frozen and placed on metal beads at -80°C.  
 Pictures were taken using an EVOS microscope while the cells were still on the 
hemocytometer used for counting (Diagram 4). Pictures were taken of CD8+ cells, CD4+ cells, 
CD19+ cells, other MNC and Granulocytes. Upon counting the bead bound cells the purity was 
assessed and 98-99 percent of cells represented were bound to magnetic beads. This purity 






A.   
B.   
C.   
Diagram 4. Validation of antigen specific bead binding for isolation of specific lymphocytes from 
patient blood samples. CD8+ Cells from Patient J cycle 3 (A.). CD4+ Cells from Patient E cycle 6 (B.). 




Statistical Analysis of Lymphocyte Counts from NSCLC Patients 
 Baseline cell counts for CD8+, CD4+ and CD19+ cells were analyzed independently of 
other cell types. All patient baseline cell counts were compiled into one group for each 
lymphocyte cell type and compared to the healthy donor counts for the respective cell type. To 
determine significance a non-paired two tailed Student’s t-test was used. Analysis was done 
using the GraphPad Prism software. 
pH Buffered Media 
 The media used to perform the pH treatments on the various cancer cell lines was an 
RPMI (Gibco) buffered media. It was found that rather than using the pKa buffers HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), MES (2-(N-morpholino) ethanesulfonic acid) 
and EPPS, the RPMI media performed well enough with only Hepes and MES alone. Two 
separate RPMI medias were created with added 7.5mM Hepes and MES. These separate medias 
were then buffered so one had a pH of 6.4 and the other had a pH of 7.4 which served as our 
physiological pH. Once the desired pH was achieved in each of these medias, the medias were 
then filtered through a .22 micron filter and stored in a 4C fridge until they were needed for cell 
treatment.  
Cell Culture 
 Cancer cell lines were cultured in media that contained 90% RPMI media with 10% Fetal 
Bovine Serum (FBS) and 1x Penicillin/ Streptomycin (Pen/ Strep). Cells were cultured to 70-90 
percent confluence before splitting and being re-seeded in p60 plates. Adherent cells were treated 
with trypsin for 5 minutes at 37°C 5% CO2 in order for the cells to detach from the plate. Cells 




following day cells were treated with the buffered RPMI media at pH 6.4 and pH 7.4 and placed 
back in the incubator for 5 hours and 24 hours as there were two durations of exposure that were 
tested. Cells were incubated at 37°C with 5% CO2. After a 5 hour period the 6.4 pH buffered 
media had increased in alkalinity to a pH of 6.47 and after 24 hours the 6.4 pH buffered media 
had increased to a pH of 6.53. The 7.4 pH buffered media showed no change in pH value at the 5 
hour mark but by 24 hours the media had increased to a pH of 7.49. 
Reverse Transcription Reaction (mRNA to cDNA) 
 RNA isolated from the cells of our cancer patients and from the cells of our pH treated 
cancer cell lines were then converted into cDNA through reverse transcription and their quality 
was confirmed through the implementation of PCR and gel electrophoresis using an 18S primer 
compatible with human cDNA. RT reactions were performed in an environment that was cleared 
of RNases before initiation of each of the individual experiments. RNA was measured using a 
nanodrop machine and then, using ultrapure RNase free water, mRNA was diluted to a 
concentration of 200 ng in 11 µl. This method of reverse transcription utilized a reverse 
transcriptase (superscript IV) (Invitrogen). Once the mRNA had been diluted in a total volume of 
11 µl master mix containing equal parts of 50 µM random hexamers (Invitrogen) and 10 mM 
dNTP (ThermoFisher) was created. 2 µl of this first master mix were then added to each of the 
separate tubes containing cDNA. This cDNA mix was then centrifuged briefly and then placed in 
a PCR machine for 5 minutes at 65°C. Samples were then removed from the PCR machine and 
placed on ice for 1 minute. A second master mix was then created at the following ratios: 4 µl 5x 
Superscript IV Buffer (Invitrogen), 1ul 100 mM DTT (Invitrogen), 1 µl Ultrapure RNase/ DNase 
free water (Gibco) and 1 µl Superscript IV 200 U/ul. 7 µl of this second master mix was then 




Samples were incubated at room temperature for 10 minutes and then placed into the PCR 
machine under RT4 protocol at 55°C for 10 minutes and then 80°C for 10 minutes. Samples 
were removed from the PCR machine once the machine had completed all of its required cycles 
and the samples were diluted 1:10 with Ultrapure RNase/ DNase free water. 
Polymerase Chain Reaction (PCR) 
 Once mRNA had been reverse transcribed into cDNA it was then paired with primers for 
18S, a ribosomal subunit that is expressed in most cell types. PCR was used to show expression 
of the genes of interest due to the ability of PCR to amplify any mRNA gene expression once the 
mRNA has been converted to cDNA and paired with primers. Since DNA cannot initiate 
synthesis on its own it must be paired with primers which bind to the DNA strand based off of a 
consensus sequence. Once bound to the DNA the primer acts as a foundation for DNA synthesis 
as nucleic acids are added onto it. By adding forward and reverse primers for a gene we only 
replicate a section of the cDNA that has that genes expression and this is done to an exact base 
pair match. Sense primers will first bind to the cDNA and code the sister strand for the entire 
length of that cDNA. The antisense primer will then bind to the newly synthesized sister strand 
and code the original cDNA but it cannot code past the point where the sense primer bound to 
the original cDNA. This process will then repeat and go on indefinitely, exponentially increasing 
the amount of gene expression on the cDNA for the primers it was paired with. PCR relies on 
thermal cycling, the act of heating and then cooling the cDNA and primers. First heat is applied 
to separate the double stranded DNA through denaturation. This is followed with a lower 
temperature that allows for the cDNA to bind to the introduced primers and then initiate 




number of times which in our case for the 18S primers the PCR machine was set to cycle 32 
times. 
  18S expression served as an indicator as to whether or not a successful reverse 
transcription reaction had occurred. The product of the PCR containing the transcribed cDNA 
and the forward and reverse 18S primers was then combined with 5 µl of 6X loading dye and 
then 15 µl of the dyed sample was loaded into a 1.5% agarose gel containing ethidium bromide 
at 0.5 µg/ 10 ml. A 100 base pair ladder was added alongside these samples to assess product 
base pair length. This gel was then administered a 100V current for 25 minutes using an 
electrophoresis tub. Once the 25 minutes had passed the gel was then placed under a UV light 
and the DNA band was photographed. 
SYBR Green qPCR Analysis 
 Once cDNA was reverse transcribed from the mRNA derived from the patient immune 
cells as well as from the pH treated cancer cell lines we then utilized SYBR Green qPCR to 
determine gene expression at the mRNA level. For each gene I combined forward and reverse 
primers that bound to a series of nucleotides unique to each individual gene, and diluted with 
ultrapure RNase / DNase free water until a concentration of 2.5 µM was achieved for each 
separate primer in the solution. For qPCR analysis, PowerUP™ SYBR™ Green Master Mix 
from ThermoFisher Applied Biosystems was used. Separate master mixes were created for each 
of the genes investigated. Master mixes were created by combining 62.5% PowerUP™ SYBR™ 
Green Master Mix with 37.5 % of the 2.5 µM forward and reverse primers for the desired gene, 
bringing the concentration of the combined primers in the Master Mix to 1.5 µM. For the qPCR 
reaction, 3 µl of cDNA from each of the samples was added to the wells of 0.2ml 96 well qPCR 




for a total reaction volume of 15 µl. Once the cDNA and the Master Mix was combined, the 96 
well plates were then covered with an optical adhesive cover and centrifuged for 3 minutes at -
2000 rpm to collect all of the mixture to the bottom of the well. The plate was then placed in a 
QuantStudio3 machine and left there until the machine completed its runtime.  
 
Once the machine had completed its cycles the CT values were given and used to 
calculate the relative expression. For patient samples and pH treated cancer cells the relative 
expression for a given gene was calculated by subtracting the CT value for the endogenous 
control gene (18S) for a specific treatment group from the CT value of a given gene from that 
same treatment group. The delta CT values were then used to calculate the delta delta CT 
(ΔΔCT) by subtracting the control group’s delta CT value from the experimental groups CT 
value. For NSCLC patients the control group was the baseline point for each individual patient 
and the experimental groups were the different collection points from baseline to post cycle 2. 
Delta CT values were used to calculate the ΔΔCT values of the patients they were observed in. 
Physiological pH treated cancer cell lines served as the control groups for the pH treated cancer 
cell lines while the acidic pH treated cancer cell groups were the experimental values. Delta delta 
CT values were calculated by taking the relative expression of a given gene for one cancer cell 
line treated with 6.4 pH buffered media and subtracting the relative expression for the same gene 
in the same cancer cell line treated with 7.4 pH buffered media. The ΔΔCT values for 5 hours 
and 24 hours were calculated separately so not to use relative expression values from different 
durations of treatment. Fold values were then calculated from delta delta CT values using the 





Gene Name Forward Primer Reverse Primer 
G2A GCAAAGAGGCTGATTGAGGAG CTCAGTGCACAGGAACCAC 
CTLA4 CTACCTGGGCATAGGCAACG CCCCGAACTAACTGCTGCAA 
PD-1 GGATGGTTCTTAGACTCCCCA TGGAGAAGCTGCAGGTGAAG 
PD-L1 TACTGTCACGGTTCCCAAGG GTGCAGCCAGGTCTAATTGT 
OGR1 CCCCTTCAGGCCCAAAGAT CCAGCACGGTAACATAGACC 
TDAG8 ACAAAGAGACAAGACTTCTCTGT AGTGATCCAGGTCATGCTGT 
CD80 ACCCTAAGCATCTGAAGCCA AGTGAGAAAGACCAGCCAGC 
CD86 GGAAGAGAGTGAACAGACCAAG TCACTTTTGTCGCATGAAGATG 
CD28 CGACTTCGCAGCCTATCG TGGCGGTCATTTCCTATCCA 
FOXP3 CACAACCTGAGTCTGCACAA CTCTGGCTCCGTTTCTTGC 
A2A CATTGACCGCTACATTGCCA GATGGCAAACGACAGCACC 
 
  
Table 1. List of Genes and the forward and reverse primers used in qPCR analysis to determine 




Cell line Medium 
Used 
205: Jurkat T cells RPMI+10% FBS+7.5mM HM 
206: PC-3, human prostate cancer cell RPMI+10% FBS+7.5mM HM 
207: Hela cells, human cervical cancer RPMI+10% FBS+7.5mM HM 
208: MCF7 cells, human breast cancer  RPMI+10% FBS+7.5mM HM 
209: Caki-1 cells, human kidney cancer RPMI+10% FBS+7.5mM HM 
211: NCI-H1299 cells, human lung cancer RPMI+10% FBS+7.5mM HM 
215: CRL-1596, Ramos cells, human B 
lymphocyte 
RPMI+10% FBS+7.5mM HM 
216: CRL-1619, A375 cells, human melanoma cell RPMI+10% FBS+7.5mM HM 
219: SK-OV-3, Ovarian Adenocarcinoma Human RPMI+10% FBS+7.5mM HM 
25: U937 wildtype Human monocyte  RPMI+10% FBS+7.5mM HM 
 
Table 2. List of cancer cell lines used for pH treatments and the media used to perform the 
treatments. 
Chapter 3: Results 
 The results section of this thesis serves to describe what effects were observed in non-
small cell lung cancer patients that were undergoing anti PD-1 immunotherapy. Results observed 
were viewed as a response to the treatment in these patients which were evaluated at cellular and 
molecular levels. First we observed how certain cells of the innate and adaptive immune system 
changed over the course of immunotherapy and we then followed these results with an 
investigation into how the mRNA levels of known immune regulatory genes and potential 
immune regulatory genes as well as GPCRs changed within cytotoxic T-cells of the adaptive 
immune system.  
 In addition to the cellular and molecular observations made in the patients of the clinical 
trial, we also began researching how changes in pH in the tumor microenvironment of various 
cancer types can alter the expression of PD-1 and its ligand PD-L1. To achieve this goal a wide 
range of human cancer cell types were utilized.  
Lung Cancer Patients Show Lower Cytotoxic T-cell counts at Baseline When Compared to 
Healthy Donors. 
 We first examined immune cell counts in 5 healthy donors to determine cell counts for 
cytotoxic T-cells, T-helper cells, B-lymphocytes, granulocytes, total MNC and other MNC. Once 
there was an established average for each of these cell populations in the healthy donor groups 
we then shifted the focus onto looking at the counts of these cell populations in patient samples. 
Isolation of the three investigated lymphocyte cell types of the adaptive immune system was 




procedure that allowed us to isolate each of the cell types by their expression of the cell specific 
markers CD8, CD4 and CD19 which represent cytotoxic T-cells, Helper T-cells and B-
Lymphocytes respectively. Initial observation of patients before beginning the anti PD-1 
immunotherapy is that the majority of these patients have low lymphocyte counts with 14 out of 
16 patients’ cytotoxic T-cell counts being below healthy donor levels at baseline (Figure 1). 
Statistical analysis of healthy donor CD8+ cell counts and patient baseline CD8+ cell counts 


















































































































































Figure 1. Baseline cytotoxic T-cell counts of Non-Small Cell Lung Cancer Patients that 
underwent anti PD-1 immunotherapy. Average cytotoxic cell count for healthy donors is 





NSCLC Patients Show Lower CD19+ B-cell Counts when Compared to Healthy Donor 
Counts 
 Using a method very similar to that used to isolate out CD8+ T-cells, we were able to 
isolate out CD19+ B-cells. To achieve this isolation of B-lymphocytes we used the same Ficoll 
gradient centrifugation previously used to layer the blood samples into the 5 distinct cell layers 
mentioned above and then we introduced CD19 antigen specific beads to these samples after 
having introduced the CD8+ and CD4+ antigen specific beads to isolate out cytotoxic T-cells 
and T-helper cells, respectively. The data shows that out of the 16 patients that were evaluated, 
12 of these patients had B-lymphocyte counts that were below that of healthy donor levels at 
baseline (Figure 2). Statistical analysis of healthy donor CD19+ cell counts and patient baseline 





















































































































































Figure 2. Baseline B-Lymphocyte counts of Non-Small Cell Lung Cancer Patients that 
underwent anti PD-1 immunotherapy. Average B-Lymphocyte count for healthy donors is 





Lower CD4+ Lymphocyte Levels Observed in NSCLC Patients when Compared to Healthy 
Donors 
 To determine the levels of CD4+ cells present in the peripheral blood of our patients, we 
implemented a method much like the methods used to isolate our CD8+ Lymphocytes and 
CD19+ Lymphocytes. First blood was separated using the previously the Ficoll centrifugation 
technique and then the CD4+ beads were isolate from the total mononuclear cell population after 
the CD8+ cells were isolated out and before the CD19+ cells were isolated. This isolation of 
CD4+ lymphocytes from the blood of these cancer patients showed us that the majority of these 
patients entered immunotherapy with already low CD4+ cell counts, 11 out of 16 patients began 
their treatment with CD4+ cell counts below that of the average healthy donor counts indicated 
by the dotted line on figure 3. Statistical analysis of healthy donor CD4+ cell counts and patient 





































































































































Figure 3. Baseline CD4+ Lymphocyte counts of Non-Small Cell Lung Cancer Patients that 
underwent anti PD-1 immunotherapy. Average CD4+ Lymphocyte count for healthy donors 





Patients Displayed an Increase in Cytotoxic T-cell Counts from Baseline within the First 
Three Cycles of Immunotherapy. 
 While patient cytotoxic T-cell counts were initially low at baseline, majority of patients 
saw an increase in their cytotoxic T-cell counts within the first three cycles of immunotherapy. 
From the entire patient population, 11 of the 16 patients showed an increase in cytotoxic T-cell 
counts within the first three cycles. Of the 16 patients, 2 patients were removed from the trial for 
health complications before they were administered a second dose of the monoclonal antibody. 
Additionally one patient that had an increase in cytotoxic T-cell counts at cycle one did not 
continue to cycle two and patients O and P are still continuing the trial and have not had their 
cell counts measured past post cycle 1. Meaning that 11 patients out of the 13 patients that 
reached a third cycle of immunotherapy displayed an increase in cytotoxic T-cell counts. Patients 
B and E exhibited cytotoxic T-cell counts at post cycle 2 that were lower than their initial counts 
at baseline while patients F and K were removed from the trial due to inabilities to continue the 







































































































Figure 4. CD8+ T-cell counts for all patients of the first three cycles of their treatments. 
(A.) Cytotoxic T-cell counts for patients A-D. (B.) Cytotoxic T-cell counts for patients E-





NSCLC Patients Treated with PD-1 Monoclonal Antibody Immune Therapy Display CD4+ 
Growth Patterns that Resemble Each Patient’s CD8+ Cell Counts 
 Much like cytotoxic T-cell counts in the NSCLC patients, CD4+ cell counts in these 
patients change over the course of immune therapy. Some patients displayed increases in CD4+ 
cells while others had decreases. However, patients seemed to follow a trend where if they 
displayed an increase in their CD8+ cell counts we would observe a corresponding increase in 
CD4+ cells and likewise, a decrease in CD8+ cells often revealed a decrease in CD4+ cell counts 
for the same patient. Although these corresponding changes were seldom to the same scale in the 

































































































Figure 5. Helper T-cell counts of NSCLC patients within the first three doses of 




Response in Cytotoxic T-cell counts in NSCLC Patients undergoing anti PD-1 
Immunotherapy is Highly Varied after the First 3 Cycles 
 As stated previously in the results, the majority of our patients undergoing anti PD-1 
immunotherapy show an increase in their cytotoxic T-cell counts within the first 3 cycles of 
treatment. However, after this point these patients show high variation in their cytotoxic T-cell 
growth rates. Some patients continue this growth in CD8+ cell counts while others will slow in 
their growth rates or even start to decline. And of patients that continue to increase their 
cytotoxic T-cell counts some exhibit a cyclical manner of proliferation while others will show a 
constant, nearly linear pattern of growth. The two patients to complete the full length of the trial, 
patients “C” and “J”, displayed similar growth patterns in their cytotoxic T-cell counts but to 








































Figure 6. Cytotoxic T-cell counts of Non-Small Cell Lung Cancer Patients that underwent 




High Variability of mRNA Expression in Cytotoxic T-cells of NSCLC Patients Undergoing 
Anti PD-1 Immunotherapy 
 To further our analysis of potential biomarkers in NSCLC patients we began to direct our 
focus towards mRNA expression of known immune regulatory genes in cytotoxic T-cells (Figure 
7). Additionally, we looked at expression levels of a family of proton sensing GPCRs in these 
isolated patient cytotoxic T-cells due to these GPCRs having previously shown to have some 
immune regulatory capacity as well as some tumorigenic capacity as well4. As can be observed 
in figure 7 of this thesis, there is a high degree of variability in mRNA expression of the 
investigated genes among cancer patients. Figure 7 shows the change in fold values for each 
specific gene from baseline and then compare among patients. Figure 7 in addition to Figure 8 
allowed for us to see which genes would warrant further investigation as can be seen in the 
following figures (10, 11, 12 and 13) which show relative expression of genes that were 



























































































































































































































Figure 7. mRNA Gene Expression (fold change is normalized to baseline mRNA 
expression) in Cytotoxic T-lymphocytes Isolated from Patient Blood Samples. 
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Changes in the Relative Expression of Genes Expressed in the Cytotoxic T-cells of NSCLC 
Patients Display Similar Trends in Cytotoxic T-cell Responsive and Unresponsive Patients 
 When examining the relative expression of the genes of interest, we observed that there 
were no distinct variations in relative expression between patients that had increases in cytotoxic 
T-cells and those that had decreases or no change in their cytotoxic T-cell counts (Figure 8). 
Higher delta CT values correspond to lower gene expression.  For all genes shown in Figure 8 of 
this thesis (CD28, TDAG8, A2A, OGR1, G2A, FOXP3 and CD86) all patients came in with 
similar relative expression levels of these genes. While some of these patients elicited unique 
trends in the expression levels of these genes over the course of immunotherapy they showed no 

































































































































































Figure 8. Relative Gene Expression (Delta CT) in Cytotoxic T-lymphocytes 




There is a “sweet spot” for Baseline PD-1 Expression in NSCLC patients undergoing anti 
PD-1 immunotherapy 
 Of the patients represented in Figure 9 of the results section of this thesis, 3 patients had 
very similar levels of relative expression of PD-1 in their cytotoxic T-cells. Additionally these 
three patients had some of the more noticeable levels of increased cytotoxic T-cell counts and 
two of these three patients had the longest survivability of all of the patients undergoing the trial. 
Additionally, patients with lower PD-1 expression (patient B and patient E) were patients that 
had decreased cytotoxic T-cell counts from when they first came into the trial. Patients A, G, H 
and I all had higher levels of relative expression of PD-1 when compared to patients C, D and J. 
However, Patients A, G, H and I did not show the same magnitude of increased cytotoxic cell 
counts as patients C, D and J with the exception of patient H who had an initial sharp increase in 



























Treatment of NSCLC Patients with anti PD-1 Antibodies Result in Varied Changes in 
levels of PD-1 mRNA Expression in the Cytotoxic T-cells of These Patients 
 Of the 9 patients that were investigated for their mRNA levels of various immune 
regulatory genes, 5 showed a decrease in their relative levels of PD-1 expression. Of these 5 
patients that showed a decrease in relative PD-1 expression, 3 had increases in their cytotoxic T-
cell counts. The 4 patients that displayed increases in their levels of relative expression of PD-1 
all had increased cytotoxic T-cell counts. The 5 patients with decreased PD-1 mRNA expression 
had more varied cytotoxic T-cell counts with 2 of the 5 patients having an overall decrease in 

























































NSCLC Patients Displayed Varied Changes in CD80 Expression in Cytotoxic T-cells 
 Of the patients that were kept on the trial for at least 3 cycles, only 3 patients saw a 
decrease in CD80 expression out of the 9 patients that were investigated for mRNA expression 
levels of the previously mentioned genes. Of these 3 patients that showed a decrease in CD80 
expression, 2 of the patients had increases in their cytotoxic T-cell counts. It should be noted 
here that patient H also exhibited decreases in relative mRNA expression of CD80 but did not 
complete a full 3 cycles of immunotherapy. The 5 other patients that had increases in CD80 
expression however had increases in their cytotoxic T-cell counts. Of the two patients that 
completed the trial and had the largest increases in cytotoxic T-cell counts from baseline, one 
patient had an overall increase in CD80 mRNA expression while the other patient had a decrease 





















































Figure 11. CD80 mRNA expression of NSCLC patients for each of the first three cycles of 




NSCLC Patients treated with Anti PD-1 Immunotherapy Display a Varied Response in 
Relative PD-L1 Expression in Cytotoxic T-cells 
 Next we furthered our investigation into gene expression by looking at PD-L1 mRNA 
expression within cytotoxic t-cells of NSCLC patients undergoing anti PD-1 immunotherapy. It 
was observed that there was a tendency for these patients to display a decrease in PD-L1 on 
cytotoxic T-cells with continued immunotherapy. Out of the total 9 patients that were used to 
determine molecular biomarkers, 6 of these patients showed a decrease in the relative expression 
of PD-L1 and of these 6 patients 5 showed increases in cytotoxic t-cell counts. The three patients 
that showed increases in relative PD-L1 expression however had increases in cytotoxic T-cell 
counts as well with the exception of patient E who had a severe drop in cytotoxic T-cell counts 
by cycle 3. Patient J which had the sharpest sustained rise in cytotoxic t-cell counts was among 




















































Figure 12. PD-L1 mRNA expression of NSCLC patients for each of the first three cycles of 




NSCLC Patients Treated with Monoclonal PD-1 Antibodies show Varied Changes in 
CTLA4 Expression on Cytotoxic T-cells 
  Continuing our investigation into immune regulatory protein expression on 
cytotoxic T-cells in immune therapy treated NSCLC patients we turned our focus to the protein 
CTLA4. When looking at the mRNA levels of expression of the immune regulator CTLA4 on 
cytotoxic T-cells we observed 6 of the 9 patients examined had overall decreased CTLA4 mRNA 
expression. Of these 6 patients with decreased CTLA4 mRNA expression, 2 had decreased 
cytotoxic T-cell counts from baseline. And all patients that had increased CTLA4 mRNA 




















































Figure 13. CTLA4 mRNA expression of NSCLC patients for each of the first three cycles of 




Human Cancer Cell Lines Treated with Acidic and Physiological Media for 5 hours 
Display PD-1 and PD-L1 Expression Levels that are Dependent on the Cancer Type 
 After extraction of the mRNA from the acidosis treated cancer cell lines and careful 
conversion of this mRNA to cDNA through the implementation of reverse transcription, we were 
then able to identify the expression levels of our genes of interest. We observed that after 5 hours 
of treatment, the expression of PD-1 and PD-L1 is highly varied among cancer types. However, 
there was still a slight trend when comparing PD-1 expression levels in these cancer cells to their 
PD-L1 levels. It was observed that the majority of the cancer cells tested (7/10) had higher 
mRNA expression levels for PD-L1 than PD-1 after 5 hours at physiological pH. Additionally, of 
the 10 cancer cell lines treated with 6.4 pH buffered media nine of the cancer cells had greater 
relative expression of PD-L1 than PD-1. Although it should be observed that both of these genes 
were well represented in these cancer cell lines but the expression levels were unique to each 




































































































































































































Figure 14. Relative expression of PD-1 and PD-L1 in cancer cell lines treated for 5 hours 




Human Cancer Cell Lines Treated with Acidic Media for 24 hours Display PD-1 and PD-
L1 Expression Levels that are Dependent on the Cancer Type 
 When comparing PD-L1 expression to PD-1 expression within individual cancer cell 
lines at 24 hours of continuous treatment physiological pH buffered media we see that 8 of the 
10 cancer cell types display PD-L1 expression that is greater than PD-1 expression after being 
treated with physiological pH buffered media. When treated with acidic pH buffered media, 8 of 
the 10 cancer cell lines showed PD-L1 expression levels that were greater than their individual 
PD-1 expression levels (Figure 15). Noticing these differences in expression levels with 5 hour 
and 24 hour treatments we then calculated the fold change for the mRNA expression of these 
genes which, normalizing to the physiological pH media treated cell lines as observed in figures 























































































































































































Figure 15. Relative expression of PD-1 and PD-L1 in cancer cell lines treated for 24 hours 




Changes in the Fold Values of PD-1 and PD-L1 Appear to be Linked to Each Other as the 
Two Genes Increase or Decrease Together in Each Cancer Cell Line 
 Similar to what was observed in Figures 14 and 15, the fold values for PD-1 and PD-L1 
vary among cancer cell lines. However, it was observed in the 5 hour pH treated cancer cell lines 
that the PD-1 and PD-L1 fold values increased and decreased in similar manners within each 
individual cancer cell line. Meaning that if an increase in one gene was observed in an individual 
cancer cell line then it was likely that an increase the other gene would be observed in the same 
cancer cell line. This pattern was observed in 6 out of the 10 cancer cell lines in the 5 hour pH 






















































































































































Acidosis Induces Changes in PD-1 mRNA Expression that is Cancer Cell Dependent after 
24 Hours of Treatment 
 
 To further evaluate the role of the PD-1/ PD-L1 checkpoint pathway on immune 
regulation and cancer prognosis we began to investigate how the expression of these proteins 
changes on cancer types when exposed to certain conditions. To start, we investigated how 
acidosis impacts the expression of these proteins in 10 different cancer cell types. Using RPMI 
media with 10% FBS and 1x Pen/ Strep with 7.5mM HEPES and MES added and then buffered 
to pH 6.4 and pH 7.4 we were able to grow these cells at an acidic pH and a physiological pH. 
Each cell line was treated in triplicates at 6.4 and 7.4 pH for 5 hours and 24 hours. I then 
extracted the RNA and protein from these treated cells and used the RNA in a reverse 
transcription reaction that yielded cDNA which was then used in qPCR to determine the mRNA 
expression of these genes at different levels of acidity at different time points. Figure 18 shows 
the difference of PD-L1 and PD-1 expression in various acidic media treated cancer cell lines 
normalized to physiological pH buffered media treated cancer cells at 24 hours. We observed 
that at 24 hours the change in PD-L1 expression levels between acidic and physiological pH 
levels was minimal. PD-1 expression was however highly varied depending on the cancer cell 
type. Visible increases can be seen in U937, Prostate, HELA and Lung cancer cell lines but all 



























































































































































PD-L1 mRNA Expression Levels in pH Treated Cancer Cell Lines Vary with the Duration 
of Exposure to Acidic Conditions 
 When comparing the mRNA expression levels of the human cancer cell lines used in this 
study we not only see varying changes in expression for PD-L1 among cancer cells but we also 
see variation in the same cancer cells at different time points. This change in PD-L1 expression 
between different durations of treatment do not appear to show any pattern. Cell lines that show 
an increase in expression at 5 hours show a decrease at 24 hours while another cell line may have 
an increase at 5 hours but then has a smaller increase in PD-L1 expression at 24 hours. However, 
both lung cancer and melanoma cell lines displayed minimal increases in PD-L1 expression at 







PD-1 mRNA Expression Levels in pH Treated Cancer Cell Lines Vary with the Duration of 
Exposure to Acidic Conditions 
 Much like the PD-L1 mRNA expression in the acidosis treated cancer cell lines, the 
mRNA expression levels of PD-1 in the cancer cell lines also had high variation between the 5 
hour and 24 hour treatments. Furthering on this likeness between the data represented in figures 
17 and 18, there was an increase in PD-1 mRNA expression in melanoma cells at 5 hours but a 
decrease in expression of PD-1 was observed in melanoma cells at 24 hours of treatment while 




Chapter 4: Discussion 
 Our goal for this study was to identify biomarkers in non-small cell lung cancer patients 
undergoing anti PD-1 immunotherapy in hopes that we would be able to identify which patients 
would respond to the treatment and at the same time pull back the metaphorical curtains on the 
role of PD-1 in cancer in order to better understand the role the receptor plays in cancer and lay 
the groundwork to further developing more cancer treatment options. To achieve this task of 
identifying biomarkers in these patients we looked at cell counts of the innate immune system 
and how these changed over the course of continued immunotherapy. Additionally we looked at 
the expression levels of known genes that had known immune regulatory capabilities. Previous 
studies investigate cell counts of cytotoxic T-lymphocytes in NSCLC patients undergoing anti 
PD-1 immunotherapy but did not report findings past the second cycle of immunotherapy and 
did not report on the cell growth of other lymphocytes of the adaptive immune system. It has 
been observed that when treated with anti PD-1 monoclonal antibodies, both melanoma and 
NSCLC patients show increased cytotoxic T-cell counts1-2. However, little genetic analysis has 
been added to this information and as stated, these cell counts in previous clinical experiments do 
not span the entire duration of the immunotherapy treatment for each of these patients as our 
study does.  
 When addressing the possibility of cytotoxic T-cell counts serving as possible biomarkers 
in NSCLC patients we looked at three different qualifications; cytotoxic T-cell counts of the 
patients at baseline, the change in cytotoxic T-cell counts within the first three cycles of 
immunotherapy for each patient and cytotoxic T-cell growth rates and fluctuations in our 




levels typically responded poorly to immunotherapy by exhibiting decreases in cytotoxic T-cell 
counts with continued immunotherapy as can be seen in patients E and L (Figure 1 and Figure 5). 
On the other hand, most patients that had cytotoxic T-cell counts lower than healthy donors and 
completed a minimum of three cycles of immunotherapy showed an increase in cytotoxic T-cell 
counts (Figure 1 and Figure 5). We then followed our investigation on the counts of cytotoxic T-
cells in our immune therapy treated NSCLC patients by looking at the counts of CD4+ T-cells. 
We observed that CD4+ cell counts also display increases and decreases in these NSCLC 
patients but in addition to this, the CD4+ cell counts showed similar growth trends with 
cytotoxic T-cells over the course of immune therapy with both cell lines increasing together in 
each individual patient or decreasing together (Figure 5 and Figure 6). Additionally, it is 
observed that the average ratio of CD4+ cells to CD8+ cells in an average healthy person is 
2:142. It is well known that CD4+ cells otherwise known as T-helper cells are directly responsible 
for the activation and survival of cytotoxic T-cells42-43. So it stands to reason that these similar 
growth curves between CD8+ and CD4+ cells are biologically significant in patient samples. 
Without CD4+ cells present in the adaptive immune system the immune system’s ability to 
display immunological memory suffers42-43. However, the current belief in immune therapy is 
that PD-1 monoclonal antibodies bind to PD-1 expressed on cytotoxic T-cells and thus prevent 
PD-1 activation induced apoptosis on these cells1-3. It is possible that this increase in CD4+ T-
cells with increased CD8+ cells is an increase in the sub population of CD4+ T-cells known as 
T-regulatory cells which are responsible for the suppression of CD8+ T-cell proliferation44. 
Future protein analysis of the CD4+ cell populations isolated from patients will have to be 
performed to accurately evaluate this potential presence of regulatory T-cells. Continuing with 




immune therapy regulates cell counts and help in our goal to identify biomarkers for these 
patients. Currently we have processed 16 patients of our total 20 patient goal. Having a sample 
size this small in number means that any observations made will have to followed in the future 
with more in depth experimentation, possibly through the recruitment of more cancer patients. 
Due to time constrains this thesis was constructed with the data collected from these 16 NSCLC 
patients. Statistical analysis was also limited due to the manner that the data was examined. 
Since each patient sample was treated as an individual data point at each treatment cycle 
longitudinally and was not added into an average, statistical analysis was impossible. 
Since anti PD-1 mAb immunotherapy serves to block cancer’s immune regulatory effects 
on cytotoxic T-cells and cause an increase in cytotoxic T-cells this may explain why some 
patients had an increase in cytotoxic T-cell counts while others did not. When looking at the 
relative expression levels of PD-1 in NSCLC patients undergoing anti PD-1 immunotherapy a 
trend can be seen. Patients with lower increases in their cytotoxic T-cell counts had higher 
baseline relative PD-1 expression values while the patients that had decreases in their cytotoxic 
T-cell counts had the lowest baseline relative PD-1 expression and patients that had the largest 
increases in cytotoxic T-cell counts are found in between these high and low spectrums of PD-1 
mRNA expression in cytotoxic T-cells extracted from baseline (Figure 10). This data seems to 
suggest a trend where the relative expression of PD-1 in the cytotoxic T-cells of NSCLC patients 
could potentially be used to determine patient outcome and thus, PD-1 mRNA expression in 
cytotoxic T-cells may serve as a biomarker for NSCLC patient response.  
 Following the investigation into PD-1 we then turned our focus to its ligand PD-L1 and 
its expression in cytotoxic T-cells.  PD-L1 expression on cytotoxic T-cells serves the same 




death in other cells expressing PD-1. However, because PD-L1 and PD-1 are both expressed on 
cytotoxic T-cells this allows the cells to self-regulate their numbers. Interestingly when we 
looked at the PD-L1 expression on the cytotoxic T-cells of these NSCLC patients undergoing the 
anti PD-1 immunotherapy we saw that 6 of the 9 evaluated patients had decreases in their PD-L1 
expression and of these 6 patients, 5 had increases in their cytotoxic T-cell counts. However, the 
additional 3 patients that had increased PD-L1 expression displayed increases in the cytotoxic T-
cell counts of 2 patients within the first three cycles of immunotherapy. Additionally, PD-1 and 
CTLA4 expression were observed to have decreased in 5 of the patients. However since the 
sample size was so small this roughly equaled to half of the patients having increases in PD-1 
and CTLA-4 expression and the other half having an increase in the expression. Future 
experiments will be necessary in order to accurately determine if and then how PD-1 immune 
therapy regulates the expression of these genes in NSCLC patients.  
 Decreasing the expression of negative immune regulators PD-1, PD-L1 and CTLA-4 on 
cytotoxic T-cells as was observed in some of the patients may have some significance to 
immunological response. By PD-1 blockade decreasing the expression of these genes, it can then 
be perceived that cells are operating on a possible negative feedback loop. By anti PD-1 
monoclonal antibodies binding to PD-1 proteins expressed on cytotoxic T-cells, the PD-1 is 
compromised and incapable of activation which then appears to have the potential result of 
decreased expression of other negative immune regulatory proteins. This negative feedback loop 
may serve as a mechanism within cytotoxic T-cells to signal for an increase in their activation. 
However, this negative feedback loop will have to be proved by additional research utilizing 
protein analysis techniques such as western blotting or ICC. These techniques when used on 




expression of the immune regulatory genes at the protein level and if the other immune regulator 
genes that did not show a trend are evaluated some significance may be found. 
Additionally, some patients showed an increase in the gene CD80 that is responsible for 
the activation of receptors CTLA4, responsible for the induction of cell death on T-cells, and 
CD28, responsible for T-cell activation and survival. CD80 is largely expressed on antigen 
presenting cells but in the presence of immune therapy it appears that they are upregulated on 
cytotoxic T-cells, perhaps to aid in self-regulation. However, since CD80 can be attributed to 
decreases and increases in T-cell activation due to the proteins in interacts with it is difficult to 
determine the role CD80 plays in anti PD-1 immune therapy. 
 Evaluation of PD-1/PD-L1 mRNA expression in cancer cell lines treated with acidic 
buffered media showed varying cellular responses that appear to be dependent on several 
variables. Some cancer cell lines had increases in PD-1 or PD-L1 mRNA expression at 5 hours 
of treatment but when examined at 24 hours of exposure were found to have reverted back to 
physiological pH levels of expression for the genes or showed to have decreased their expression 
to below that of physiological levels. Additionally different cancer cell lines exhibited different 
regulation patterns for these genes when compared to other cells leading me to believe that the 
expression of PD-1 and PD-L1 and how an acidic TME regulates these expression levels is 
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